Document is current
Any future updates will be listed below
-
Authors
Koutarapu, Srinivas
Ge, Junyue https://orcid.org/0009-0005-9542-802X
Dulewicz, Maciej https://orcid.org/0000-0002-7149-017X
Srikrishna, Meera
Szadziewska, Alicja https://orcid.org/0000-0002-8377-9309
Wood, Jack https://orcid.org/0000-0001-6049-4020
Blennow, Kaj https://orcid.org/0000-0002-1890-4193
Zetterberg, Henrik https://orcid.org/0000-0003-3930-4354
Michno, Wojciech https://orcid.org/0000-0002-3096-3604
Ryan, Natalie S.
Lashley, Tammaryn https://orcid.org/0000-0001-7389-0348
Savas, Jeffrey N. https://orcid.org/0000-0002-8173-5580
Schöll, Michael https://orcid.org/0000-0001-7800-1781
Hanrieder, Jörg https://orcid.org/0000-0001-6059-198X
- License Information
-
More Information
Article History
Received: 8 June 2024
Accepted: 9 April 2025
First Online: 24 April 2025
Competing interests
: H.Z. has served at scientific advisory boards and/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Amylyx, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, Merry Life, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Alzecure, Biogen, Cellectricon, Fujirebio, Lilly, Novo Nordisk, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). KB has served as a consultant, at advisory boards, or at data monitoring committees for Abcam, Axon, BioArctic, Biogen, JOMDD/Shimadzu. Julius Clinical, Lilly, MagQu, Novartis, Ono Pharma, Pharmatrophix, Prothena, Roche Diagnostics, and Siemens Healthineers, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program, outside the work presented in this paper. The remaining authors declare no competing interests.
